Volume 133, Issue 3, Pages 790-798 (September 2007) Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs  Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter E. Smalley, Kathi Hall, Patrick G. Arbogast, Marie R. Griffin  Gastroenterology  Volume 133, Issue 3, Pages 790-798 (September 2007) DOI: 10.1053/j.gastro.2007.06.058 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Adjusted incidence of peptic ulcer–related hospitalizations for NSAID and coxib users, according to gastroprotective cotherapy. The left y-axis shows the adjusted rate of hospitalizations per 1000 person-years (PY) of follow-up; the right y-axis shows the IRR. Vertical bars are 95% CIs. The reference group is former users of either NSAIDs or coxibs with no gastroprotective cotherapy. All rates and IRRs are adjusted for baseline demographic factors, baseline history of upper gastrointestinal disease, baseline medical comorbidity, use of medications that cause upper gastrointestinal bleeding (baseline and during follow-up), and hospital or nursing home admission during follow-up. The person-years of follow-up were as follows: 57,032 (NSAID, no gastroprotective cotherapy), 10,625 (NSAID, gastroprotective cotherapy), 13,962 (coxib, no gastroprotective cotherapy), 7,025 (coxib, gastroprotective cotherapy), and 135,758 (former). Data shown in the figure exclude 120,640 person-years for indeterminate users and 17,995 for former users with concurrent gastroprotective cotherapy. Gastroenterology 2007 133, 790-798DOI: (10.1053/j.gastro.2007.06.058) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Subgroup analyses. Adjusted incidence of peptic ulcer–related hospitalizations in users of NSAIDs with concurrent proton pump inhibitor (PPI) use or users of coxibs without or with concurrent PPI use. The chart depicts the IRR and 95% CIs, with the reference category that of NSAID users with no gastroprotective cotherapy. All rates and IRRs are adjusted for baseline demographic factors, baseline history of upper gastrointestinal disease, baseline medical comorbidity, use of medications that cause upper gastrointestinal bleeding (baseline and during follow-up), and hospital or nursing home admission during follow-up. The rate in parentheses after the subgroup description is the adjusted rate in that subgroup of peptic ulcer–related hospitalizations per 1000 person-years (PY) among NSAID users with no gastroprotective cotherapy. “Past ulcer” is defined as diagnosis of peptic ulcer disease or gastritis in the 2 years preceding start of follow-up, “medical comorbidity” is defined as the upper quintile of summary medical comorbidity score, and “low dose aspirin” is defined as current use of low-dose aspirin; antiplatelet drugs are dipyridamole, ticlopidine, or clopidogrel. Gastroenterology 2007 133, 790-798DOI: (10.1053/j.gastro.2007.06.058) Copyright © 2007 AGA Institute Terms and Conditions